ONWARD Medical has announced the appointment of Professor Tim Denison, a globally respected neurotechnology expert, to its Board of Directors. As a leading figure in bioelectronics and neural engineering, Denison brings extensive experience from both academia and industry, including his tenure as Vice President at Medtronic and his current role at the University of Oxford. His contributions to the development of next-generation neural interfaces and neuromodulation algorithms directly align with ONWARD’s mission to restore movement and function in people living with spinal cord injury (SCI) and neurological disorders. Denison’s addition to the Board reflects a strategic move to strengthen ONWARD’s innovation pipeline with world-class technical insight.
The appointment follows the transition of Professor Grégoire Courtine—ONWARD’s Co-Founder and former Board member—into a dedicated Science Advisor role. Courtine, who co-developed ONWARD’s core technologies, is stepping away from the Board to focus on his leadership of the Neuro-X Institute and NeuroRestore, while continuing to support ONWARD’s scientific progress. Denison, who has co-authored multiple pivotal studies with Courtine, is uniquely positioned to carry forward the legacy of translational neurotechnology while offering an expanded vision at the interface of clinical and commercial strategy. His presence on the Board strengthens ONWARD’s commitment to driving clinically validated, next-generation neuromodulation therapies toward commercialization.
These changes come alongside the reappointment of key Board members, including CEO Dave Marver and Non-Executive Directors Ian Curtis, Rob ten Hoedt (now Chairman), and Rahma Samow. This revised Board structure reflects a balanced mix of operational leadership, scientific excellence, and strategic oversight, poised to guide ONWARD through its next phase of growth. With Denison’s appointment and Courtine’s continued involvement, ONWARD reinforces its leadership in neurotechnology innovation—positioning the company to deliver meaningful breakthroughs in restoring independence and mobility for individuals living with debilitating movement disorders.
MedTech Spectrum's Summary
Strategic Leadership Strengthening: ONWARD Medical’s appointment of Professor Tim Denison to the Board brings world-class expertise in neurotechnology and bioelectronics, ensuring continued innovation and informed strategic direction as the company advances its neuromodulation therapies.
Scientific Continuity and Innovation: Denison’s deep familiarity with ONWARD’s core science—developed alongside Co-Founder Grégoire Courtine—ensures scientific continuity while expanding the Board’s capabilities to translate cutting-edge research into impactful clinical applications.
Future Growth and Market Readiness: With a newly reinforced Board, including reappointments of key executives and the transition of Courtine to Science Advisor, ONWARD is well-positioned to accelerate clinical programs, prepare for commercialization, and drive long-term impact in restoring movement and function for patients with spinal cord injuries and related disorders.
